Nastech Pharma (NSTK) Director Buys 10K Shares
More News related to NSTK
- Nastech (NSTK) Announces Positive Intranasal Insulin Data
- Nastech Pharma (NSTK) Director Buys 10K Shares
- Unusual 11 Mid-Day Movers 4/25: HDY, XJT, VNDA, YRCW Higher; NSTK, ISIS, FBR, PGNX Lower
- Pre-Open Movers 2/25:Progenics Pharma (PGNX) Jumps On FDA Approval, Netgear (NTGR) Down on Results
- Nastech Pharmaceutical (NSTK) Sells 4.58M Shares at $1.73
Nastech Pharmaceutical (Nasdaq: NSTK) Director, Gerald Stanwick, bought 10,000 shares on 5/12 at $1.14.
Shares of NSTK are trading at 52-week low levels.
Nastech Pharmaceutical Company, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on proprietary molecular biology-based nasal drug delivery technology and proprietary ribonucleic acid interference (RNAi) technology.
Related Categories
Insider TradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
